merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The safety risks associated with the drug, including swelling and bleeding in the brain.</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for treatments that could be better.</answer>
<question_number>3</question_number>
<answer>He says there's no correlation.</answer>
<question_number>4</question_number>
<answer>It could negatively impact the perception of Kisunla's safety.</answer>
<question_number>5</question_number>
<answer>The expectation that patients can stop taking it after their plaques are cleared.</answer>
<question_number>6</question_number>
<answer>It might discourage patients from participating in trials for treatments that could be better.</answer>
<question_number>7</question_number>
<answer>Patients can stop taking it after their plaques are cleared.</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>